Patent ID: 8168592

Claim:
A composition of matter, comprising a CGRP peptide antagonist comprising an amino acid sequence of the formula: (SEQ ID NO: 1127) Xaa 1 Xaa 2 Xaa 3 Xaa 4 Xaa 5 Xaa 6 Xaa 7 V 8 Xaa 9 Xaa 10 Xaa 11 L 12 A 13 G 14 L 15 L 16 S 17 Xaa 18 S 19 G 20 G 21 V 22 Xaa 23 Xaa 24 Xaa 25 Xaa 26 F 27 V 28 P 29 Xaa 30 Xaa 31 V 32 G 33 Xaa 34 Xaa 35 A 36 Xaa 37 wherein: Xaa 1 , Xaa 2 , Xaa 3 Xaa 4 , Xaa 5 , Xaa 6 , and Xaa 7 , are each independently absent or a hydrophobic amino acid residue selected from Trp, 1-Nal, 2-Nal, Phe, Tyr, Bip, 4-carboxy-phenylalanine, and 4-Amino-Phe; Xaa 9 is a Thr, Ser, Ala, Gly, Val, Leu, or Ile residue; Xaa 10 is a His, N α -Methyl-His, Lys, Homolysine, Ornithine, or 4-Amino-Phe residue; Xaa 11 is an N α -Methyl-Arg, homoarginine, Cit, N α -Methyl-Cit, Homocitrulline, His, Guf, Lys, Homolysine, Ornithine, or 4-Amino-Phe residue; Xaa 18 is an N α -Methyl-Arg, homoarginine, Cit, N α -Methyl-Cit, Homocitrulline, His, Guf, Lys, Homolysine, Ornithine, or 4-Amino-Phe residue; Xaa 23 is a Val, Arg, D-Arg, homoarginine, Lys, D-Lys, homolysine, Orn, Dab, Dpr, homocysteine, or 4-Amino-Phe residue; Xaa 24 is an Arg, D-Arg, Homoarginine, Lys, D-Lys, Homolysine, Orn, Dab, Dpr, Homocysteine, or 4-Amino-Phe residue; Xaa 25 is an Arg, D-Arg, Homoarginine, Lys, D-Lys, Homolysine, Orn, Dab, Dpr, Homocysteine, or 4-Amino-Phe residue; Xaa 26 is an Asn, Arg, D-Arg, Homoarginine, Lys, D-Lys, Homolysine, Orn, Dab, Dpr, Homocysteine, or 4-Amino-Phe residue; Xaa 30 is a Thr, N α -Methyl-Thr, Ser, or N α -Methyl-Ser residue; Xaa 31 is an Asn, Lys, Homolysine, Ornithine, 4-carboxy-phenylalanine, 4-Amino-Phe, beta-glutamic acid, beta-Homoglutamic acid, homoglutamic acid, or Asp residue; Xaa 34 is an Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, or Pip residue; Xaa 35 is a Phe, D-Phe, Tyr, 1-Nal, 2-Nal, Trp, or Bip residue; and Xaa 37 is a Phe, Tyr, 1-Nal, 2-Nal, Trp, Bip, 4-carboxy-phenylalanine, or 4-Amino-Phe residue.